Recombinant protective antigen vaccines - Pfenex

Drug Profile

Recombinant protective antigen vaccines - Pfenex

Alternative Names: Glide anthrax vaccine; Px 563L; Px-563L SDI; Px563L-mrPA; RPA 563; rPA anthrax vaccine - Pfenex; SDI rPA anthrax vaccine - Pfenex

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator Pfenex
  • Developer Immunovaccine; Pfenex; US Department of Health and Human Services
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Anthrax

Most Recent Events

  • 08 Aug 2016 Safety and immunogenicity results from a phase Ia trial in healthy volunteers released by Pfenex
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral, Needle-free injection)
  • 01 Dec 2015 Phase-I clinical trials in Anthrax (In volunteers, Prevention) in USA (IM) (NCT02655549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top